AOM Infusion ("AOM"), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma’s limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Did you know that a component of your blood could be used ...
"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...
Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
Preterm newborns are susceptible of invasion by microorganisms due to immaturity of their immune system. This study aimed at assessing the effect of IV immunoglobulins as supportive treatment in ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
The intravenous immunoglobulin market has seen significant growth over the last few years, driven by a combination of factors, including the increasing incidence of autoimmune and inflammatory ...
TEANECK, N.J., June 27, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of data at the 2025 Clinical Immunology Society (CIS) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results